Express News | CEL-SCI Announces Publication From Prior 3 Study Of Multikine In Journal 'Pathology and Oncology Research'

BenzingaMar 24 09:07 ET

CEL-SCI Reports New Data: Treatment With Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

BusinesswireMar 24 09:00 ET

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket

BenzingaMar 18 06:04 ET

CEL-SCI Announces Pricing of $2.5 Million Offering

BusinesswireMar 17 15:24 ET

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks With Potential Partners Interested in Commercialization of Multikine

BusinesswireMar 17 08:00 ET

CEL-SCI Announces That A Third-Party Study Published In Jama Oncology Titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-stratified Chemoradiation Therapy In HPV-Negative Head And Neck Cancer: The DEPEND Phase 2 Non-Randomized...

BenzingaMar 14 08:32 ET